A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.